2018
DOI: 10.1080/10799893.2019.1590410
|View full text |Cite
|
Sign up to set email alerts
|

The c-Jun N-terminal kinase signaling pathway in epilepsy: activation, regulation, and therapeutics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 63 publications
0
5
0
Order By: Relevance
“…MAPK (mitogen-activated protein kinase) is involved in reaction to physiological and pathological stimuli, such as cytokines, neurotransmitters, hypoxia, and hypoglycemia [53]. MAPK3 (MAP kinase ERK1) and MAPK1 (MAP kinase ERK2) form ERK1/2, a subfamily of MAPK.…”
Section: Discussionmentioning
confidence: 99%
“…MAPK (mitogen-activated protein kinase) is involved in reaction to physiological and pathological stimuli, such as cytokines, neurotransmitters, hypoxia, and hypoglycemia [53]. MAPK3 (MAP kinase ERK1) and MAPK1 (MAP kinase ERK2) form ERK1/2, a subfamily of MAPK.…”
Section: Discussionmentioning
confidence: 99%
“…The activation of JNK/MAPK signaling pathway occurs at both acute and chronic stages of epileptic development. It participates in astrocyte activation, neuronal death and mossy fiber sprouting [67]. The MAPK signaling pathway regulates RNA-binding proteins (RBPs), which are responsible for mRNA translation.…”
Section: Mapk Signaling Pathwaymentioning
confidence: 99%
“…Blocking ERK1/2 signaling prevented epileptiform behavior in rats [ 51 , 52 ]. Additionally, several studies have shown that JNK is abnormally activated in epileptic models and is related to cell death [ 53 , 54 ]. The p38 inhibitor SB203580 decreased pathological damage to the hippocampus and reduced the epileptic frequency [ 55 ].…”
Section: Discussionmentioning
confidence: 99%